Treatment Options for Women with Low Libido and Difficulty Achieving Orgasm

First-Line Treatment Options

• The National Comprehensive Cancer Network recommends flibanserin (100 mg daily at bedtime) as a first-line treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), with modest efficacy of approximately 1 additional satisfying sexual event every 2 months compared to placebo 1
• Discussion of mechanical options, including vibrators or clitoral stimulatory devices, with referral to appropriate specialists for women with orgasm difficulties is recommended 2
• Pelvic physical therapy can help with orgasm difficulties and overall sexual function 2

Second-Line/Off-Label Options

• Bupropion is considered an off-label option for women with HSDD, despite limited safety and efficacy data 1
• Androgens may be discussed for women with low desire, though not FDA-approved specifically for HSDD 2

Important Considerations

• Phosphodiesterase type 5 inhibitors (PDE5i) are NOT recommended for female sexual dysfunction due to contradictory results in clinical trials and lack of data regarding their effectiveness in women 1, 3, 4
• Psychological factors often contribute significantly to sexual dysfunction and should be addressed through appropriate referrals for anxiety, depression, or other psychological concerns 2, 5
• Lifestyle modifications, including increased physical activity, stress reduction, and addressing relationship issues, can improve sexual function 3

Special Populations

• Cancer survivors require careful consideration of treatment options, particularly those with hormone-sensitive cancers 1, 2
• Postmenopausal women may benefit from ospemifene for concurrent dyspareunia (painful intercourse), but this is contraindicated in women with a history of estrogen-dependent cancers 1, 2

Common Pitfalls and Caveats

• Current pharmacological treatments show limited effectiveness, with flibanserin resulting in only about one additional satisfying sexual event every two months 1
• "Restorative or regenerative" therapies lack robust clinical trial data and FDA approval 3

Medications for Female Hypoactive Sexual Desire Disorder (HSDD)

First-Line Treatment Options

• The American College of Obstetricians and Gynecologists recommends flibanserin as the first-line FDA-approved medication for premenopausal women with HSDD, with bremelanotide as an alternative FDA-approved option 6, 7, 8
• Bremelanotide is FDA-approved for premenopausal women with HSDD and is used as a self-administered subcutaneous injection as needed, with a mechanism of action as a melanocortin receptor agonist 6, 8
• Flibanserin results in approximately 1 additional satisfying sexual event every 2 months compared to placebo in premenopausal women with HSDD 6, 8

Second-Line/Off-Label Options

• Bupropion is considered an off-label option for premenopausal women with HSDD, with limited safety and efficacy data but considered an option by expert panels 6, 7, 8, 9
• Buspirone is considered an off-label option for premenopausal women with HSDD, with limited data but considered an option by expert panels 6, 7, 8, 9, 10

Special Considerations

• Ospemifene is FDA-approved for dyspareunia in postmenopausal women but is not specifically indicated for HSDD, and may be considered for those with concurrent dyspareunia and no history of estrogen-dependent cancers 8, 9
• Phosphodiesterase type 5 inhibitors are not recommended for female sexual dysfunction due to limited and contradictory evidence 8, 9, 10
• For cancer survivors with HSDD, treatment options should be carefully selected based on cancer type, particularly for hormone-sensitive cancers 8, 9

Treatment Algorithm

• For premenopausal women, first-line treatment options include flibanserin 100 mg daily at bedtime or bremelanotide as needed 6, 8
• For postmenopausal women, consider off-label use of flibanserin or ospemifene for those with concurrent dyspareunia and no history of estrogen-dependent cancers 8, 9
• For patients with contraindications or intolerance to first-line options, consider off-label use of bupropion or buspirone 6, 8, 9

Comparative Efficacy of Flibanserin vs. Bremelanotide for HSDD

Important Considerations

• The National Comprehensive Cancer Network notes that data on the efficacy of HSDD treatments in cancer survivors or postmenopausal women is limited, with most studies focusing on premenopausal women 11

Combined Use of Flibanserin and Gabapentin in Premenopausal Women with Hypoactive Sexual Desire Disorder

Safety and Drug‑Interaction Profile

• Gabapentin has no known pharmacokinetic or pharmacodynamic drug interactions, making it compatible with flibanserin for concurrent therapy in premenopausal women with HSDD. 12
• Gabapentin possesses no absolute contraindications, supporting its safe co‑administration with other central nervous system‑active agents such as flibanserin. 13
• Unlike SSRIs/SNRIs, gabapentin does not induce sexual dysfunction, which is advantageous when treating HSDD. 12

Efficacy of Gabapentin for Common Indications

• In neuropathic pain, gabapentin demonstrates clinically meaningful analgesic efficacy. 13
• For menopausal hot flashes, gabapentin reduces frequency by approximately 49 %–54 % compared with a 21 %–31 % reduction observed with placebo. 12

Central Nervous System (CNS) Side‑Effect Monitoring

• Both flibanserin and gabapentin can cause somnolence and dizziness; clinicians should monitor patients for additive sedation and dizziness. 13
• Up to 20 % of patients experience gabapentin‑related dizziness, unsteadiness, or drowsiness, which typically improve after the first week and resolve by week 4. 12
• Gabapentin dosing may be staggered or adjusted to avoid overlapping peak CNS effects if sedation becomes problematic. 13
• Gabapentin has a rapid onset of action (less than 1 week), allowing early assessment of tolerability and CNS side‑effects. 12

Metabolic and Endocrine Considerations

• Gabapentin can cause weight gain, a factor that may indirectly affect reproductive endocrine function and exacerbate HSDD through insulin‑resistance mechanisms. 14

Clinical Recommendations for Combined Therapy

• Prefer gabapentin over SSRIs/SNRIs for managing menopausal hot flashes in patients with HSDD because it does not worsen sexual desire. 13
• Adding gabapentin to an SSRI/SNRI regimen does not provide additional benefit for hot‑flash control. 12
• During the first 1–4 weeks of combined therapy, assess patients for excessive sedation or dizziness, the period when gabapentin‑related CNS effects are most prominent. 13
• Monitor body weight periodically to detect gabapentin‑associated weight changes that could impact HSDD outcomes. 14
• Evaluate flibanserin’s therapeutic response at 4 weeks; lack of improvement by this time suggests unlikely efficacy. 12